Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Defence Therapeutics Inc
(OP:
DTCFF
)
0.4683
-0.0507 (-9.77%)
Streaming Delayed Price
Updated: 2:56 PM EDT, Aug 30, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
2,000
Open
0.4683
Bid (Size)
N/A (0)
Ask (Size)
N/A (0)
Prev. Close
0.5190
Today's Range
0.4683 - 0.4683
52wk Range
0.4381 - 2.500
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Defence’s Successful Submission of an Investigational New Drug (IND) Application for AccuTOX(R) as an Injectable Anticancer Treatment for Solid Tumors
November 14, 2023
(November 14, 2023) - Defence Therapeutics Inc. (CSE:DTC) (OTC Pink:DTCFF) (FSE:DTC) ("Defence" or the "Company"), one of the leading Canadian biotechnology companies working in
Via
PressReach
Exposures
Product Safety
Global Oncology Drugs Market Size Projected to Reach $484 Billion by 2030
November 14, 2023
EQNX::TICKER_START (OTCPK:DTCFF),(CSE:DTC),(NYSE:BMY),(NYSE:NVS),(NYSE:MRK),(OTCQX:RHHBY) EQNX::TICKER_END
Via
FinancialNewsMedia
Performance
YTD
-71.45%
-71.45%
1 Month
-14.76%
-14.76%
3 Month
-42.89%
-42.89%
6 Month
-64.47%
-64.47%
1 Year
-78.72%
-78.72%
More News
Read More
Defence Therapeutics Key Platform Patent Accepted Broadly Covering Vaccine Technology
November 07, 2023
Via
PressReach
Topics
Intellectual Property
Exposures
Intellectual Property
Global Cancer Vaccines Market Share Is Expected To Reach $19.27 Billion By 2030
October 25, 2023
Via
FinancialNewsMedia
Defence’s Novel Accutox(TM) Continues to Surprise on Results Against Cancer
October 18, 2023
Via
PressReach
Exposures
Product Safety
Bristol Myers Squibb Enters the Multi-Billion-Dollar Oncology Race
October 17, 2023
Via
PressReach
Elli Lilly Joins Big Pharma’s Multi-Billion-Dollar Oncology Race
October 10, 2023
Via
PressReach
Defence Announces Peer-reviewed Publication of Its Preclinical Data on Accum(R) as an Anti-Cancer Molecule in the Journal of Cancer Science
October 10, 2023
Via
PressReach
Defence’s Accum(R)-mRNA Lipid Nanoparticles Elicit Antibody Response 2X Stronger than Standard mRNA Vaccines
September 26, 2023
Via
PressReach
BTV Investor Alert - Defence Therapeutics: Developing Immune-Related Therapies for Cancer Treatment
May 10, 2023
Via
Newsfile
BTV Features: Champion Iron Limited, Defence Therapeutics, Nouveau Monde Graphite, Talisker Resources, Osisko Development & more on FOX Business News
May 04, 2023
Via
Newsfile
Topics
Supply Chain
Exposures
Supply Chain
Defence Therapeutics Is Granted Patents in Japan and Israel Expanding Its Novel ADC Platform Technology in the Fast Growing Antibody-Drug Conjugates Market
September 29, 2022
Via
Newsfile
Topics
Death
Intellectual Property
Exposures
Death
Intellectual Property
Breakthrough Results with Accum(TM) A1-Reprogrammed MSC, Mesenchymal Stem Cells, in a Novel Vaccine Cured 80% of Animals with Pre-Established Lymphoma
September 21, 2022
Via
Newsfile
Defence Therapeutics Applauds United States President Biden Cancer Moonshot Initiative
September 16, 2022
Via
Newsfile
Defence Therapeutics Scores Again With New Planned Phase 1 Trial Evaluating Its DC Cancer AccuVAC-D002 Against Melanoma; Puts Second Catalyst In Play (OTCMKTS: DTCFF)
October 19, 2021
Via
AB Newswire
Defence Therapeutics ACCUM™ Technology Can Be A Treatment Game-Changer And Beating Breast Cancer Is In Its Crosshairs (OTCMKTS: DTCFF)
October 12, 2021
Via
AB Newswire
Defence Therapeutics Draws Interest As Planned Phase 1 Breast Cancer Drug Trial Nears; Posts 116% Gain Since May (OTCMKTS: DTCFF)
October 05, 2021
Via
AB Newswire
Defence Therapeutics Is Advancing Next-Generation Vaccine Technology To Beat Cancers And Virus, Even After They Mutate (OTCMKTS: DTCFF)
September 28, 2021
Via
AB Newswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.